May. 2 at 2:12 AM
$SGMT has a first-line acne drug with a potential TAM exceeding
$1 billion annually and holds global rights excluding China. Despite this, its market capitalization is only about half of the projected yearly sales. In contrast,
$CELC has a second-line cancer drug partnered with
$PFE , with a possible TAM under
$2.5 billion, yet its market cap exceeds
$6 billion.
$QQQ $SPY